Evaxion A/S (NASDAQ:EVAX – Get Free Report) and Fulgent Genetics (NASDAQ:FLGT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Risk and Volatility
Evaxion A/S has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.
Profitability
This table compares Evaxion A/S and Fulgent Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evaxion A/S | N/A | -73.56% | -37.45% |
| Fulgent Genetics | -23.04% | -3.24% | -2.97% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evaxion A/S | 1 | 0 | 5 | 0 | 2.67 |
| Fulgent Genetics | 1 | 2 | 2 | 0 | 2.20 |
Evaxion A/S presently has a consensus target price of $11.00, indicating a potential upside of 209.86%. Fulgent Genetics has a consensus target price of $27.00, indicating a potential upside of 40.99%. Given Evaxion A/S’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Evaxion A/S is more favorable than Fulgent Genetics.
Earnings and Valuation
This table compares Evaxion A/S and Fulgent Genetics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evaxion A/S | $7.53 million | 3.93 | -$7.71 million | ($1.47) | -2.41 |
| Fulgent Genetics | $322.67 million | 1.69 | -$60.51 million | ($2.39) | -8.01 |
Evaxion A/S has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Evaxion A/S beats Fulgent Genetics on 9 of the 14 factors compared between the two stocks.
About Evaxion A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
About Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.
